{"title": "Fluzone, Fluzone High-Dose and Fluzone Intradermal", "author": "Center; Research", "url": "https://www.fda.gov/vaccines-blood-biologics/vaccines/fluzone-fluzone-high-dose-and-fluzone-intradermal", "hostname": "fda.gov", "description": "Sanofi Pasteur, Inc.", "sitename": "FDA", "date": "2023-02-13", "cleaned_text": "Indication: - Fluzone is indicated for active immunization of persons 6 months of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. - Fluzone High-Dose is indicated for active immunization of persons 65 years of age and older against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. - Fluzone Intradermal indicated for active immunization for use in adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Product Information Supporting Documents [July 2, 2019 Approval Letter - Fluzone Quadrivalent and Fluzone [January 23, 2019 29, 2018 Approval Letter- Fluzone](/media/114405/download?attachment) Approval Letter - Fluzone](/media/110589/download?attachment) [July 7, 2017 Approval Letter "}